Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 17/20 | 0.68 |
| ▸ | CASP7 | P55210 | 13/20 | 0.68 |
| ▸ | CASP1 | P29466 | 8/20 | 0.68 |
| ▸ | CASP9 | P55211 | 6/20 | 0.68 |
| ▸ | CASP4 | P49662 | 3/20 | 0.53 |
| ▸ | CASP10 | Q92851 | 3/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.53 |
| ▸ | CASP5 | P51878 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317466 | 0.93 | CASP3 (0.62) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL20543505 | 0.90 | CASP3 (0.58) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL158671 | 0.90 | CASP1 (0.56) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL29362585 | 0.89 | CASP3 (0.76) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL17326941 | 0.89 | CASP3 (0.72) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL29732392 | 0.88 | CASP3 (0.71) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL20239336 | 0.88 | CASP3 (0.71) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL811863 | 0.87 | CASP3 (0.55) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL28840715 | 0.87 | CASP3 (0.55) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL2038936 | 0.86 | CASP3 (0.69) | CASP3CASP7CASP1CASP9CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20040198716-A1 | Cysteine protease inhimbitors | ARAD DORIT (US) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | MYC, CCNE2, CCNE1 | CASP3 1157/4885CASP7 1570/4885CASP1 2057/4885 |
| US-20040198716-A1 | Cysteine protease inhimbitors | CTRL, PREP, CLPP | CASP3 98/4885CASP7 235/4885CASP1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.